NCT03184571 - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 2, 2017

Primary Completion Date

October 27, 2022

Study Completion Date

October 27, 2022

Conditions

Lung Cancer MetastaticNSCLC Stage IVAdenocarcinoma of Lung

Interventions

DRUG

Pembrolizumab

Pembrolizumab is a PD-1 inhibitor

DRUG

Bemcentinib

Bemcentinib is a selective Axl kinase inhibitor;

Trial Locations (13)

Hospital Teresa Herrera, A Coruña

Hospital Universitario Fundacion Jimene Diaz, Madrid

Hospital Universitario 12 de Octubre, Servicio de oncologia, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Dartmouth-Hitchcock Medical Center (DHMC), Lebanon

Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee

Radiumhospitalet, Oslo University Hospital PB, Oslo

Hospital Universitari Germans Trias i Pujol-ICO, Barcelona

Servicio de Oncologia Hospital del Mar, Barcelona

Hospital Universitario Vall d'Hebron (VHIR), Barcelona

Hospital Clinic Barcelona, Barcelona

Guy's and St Thomas' NHS Foundation Trust, London

Christie NHS Hospital Foundation Trust, Manchester